Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

Area of Science:

• Immunology
• Allergy Research
• Pharmacology

Background:

• Omalizumab targets circulating IgE, preventing mast cell and basophil activation.
• Previous studies show omalizumab rapidly reduces IgE and basophil Fc epsilon RI receptors.
• Tissue mast cell changes were hypothesized but not fully elucidated.

Purpose of the Study:

• To investigate the phenotypic changes in skin mast cells alongside blood basophils during omalizumab therapy.
• To compare the time course of Fc epsilon RI receptor expression in skin mast cells versus blood basophils.

Main Methods:

• Three allergic rhinitis subjects received omalizumab and underwent allergen skin testing and biopsy at multiple time points.
• Control subjects (n=5) with allergic rhinitis were evaluated similarly without treatment.
• Skin biopsies were analyzed via immunohistochemistry for Fc epsilon RI alpha and tryptase expression.

Main Results:

• Omalizumab recipients showed decreased Fc epsilon RI alpha immunoreactivity on skin mast cells at 70 and 196 days.
• This decrease correlated with reduced acute wheal responses to allergen.
• No significant reduction in tryptase-positive mast cells was observed during the study period.

Conclusions:

• Omalizumab effectively reduces Fc epsilon RI receptor expression on both basophils (rapidly) and skin mast cells (more slowly).
• The slower modulation of Fc epsilon RI on skin mast cells is linked to diminished acute allergic wheal reactions.
• Findings highlight differential kinetics of Fc epsilon RI downregulation on immune cells by omalizumab.